Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06169319 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
NCT06169319: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT06169319 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 231 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06169319, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
Study Summary
This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Collagenase Clostridium Histolyticum (CCH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2024-01-03 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06169319
The ClinicalTrials.gov registry entry for NCT06169319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06169319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06169319 about?
NCT06169319 is a clinical study titled "A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)". This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.
What is the current status of trial NCT06169319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2024-01-03. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT06169319?
The interventions under investigation include: Placebo (BIOLOGICAL), Collagenase Clostridium Histolyticum (CCH) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06169319?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.